Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pharmacokinetics, Safety and Tolerability of Twice-Daily Aclidinium Bromide/Formoterol Fumarate Fixed Dose Combination in Chinese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03276078
Recruitment Status : Completed
First Posted : September 8, 2017
Results First Posted : July 22, 2019
Last Update Posted : July 22, 2019
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
A Phase IIa, open-label, repeat-dose trial to investigate the pharmacokinetics (PK), safety and tolerability of single and multiple twice daily doses of inhaled Aclidinium Bromide/Formoterol Fumarate 400/12 μg in 20 Chinese male and female patients with stable moderate to severe COPD.

Condition or disease Intervention/treatment Phase
Pulmonary Disease, Chronic Obstructive Drug: Aclidinium Bromide/Formoterol Fumarate 400/12μg BID Phase 2

Detailed Description:

Screening will be performed within 21 days of dosing on Day 1 at visit 2. Eligible participants will be admitted to the trial center the day preceding the first dosing (day -1).

Participants will receive Aclidinium Bromide/Formoterol Fumarate 400/12 μg twice-daily (morning and evening) on Days 1 to 4. On Day 5 patients will receive the morning dose only. PK and safety assessments will be conducted at specific timepoints on Day 1 to Day 7.

Participants will be discharged 48 h after the last administration of investigational product and completion of the 48-h PK sample collection and safety assessments on Day 7.

A follow-up visit will be performed within 5 days of the last PK sample collection on Day 7.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase IIa, Open-Label, Repeat-Dose Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Fixed Dose Combination Administered Twice-Daily by Inhalation in Chinese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Actual Study Start Date : November 23, 2017
Actual Primary Completion Date : June 12, 2018
Actual Study Completion Date : June 12, 2018


Arm Intervention/treatment
Experimental: Aclidinium Bromide/Formoterol Fumarate 400/12μg BID
Aclidinium bromide/Formoterol Fumarate 400/12μg inhalation powder twice-daily. Oral inhalation via Genuair® dry powder inhaler (DPI).
Drug: Aclidinium Bromide/Formoterol Fumarate 400/12μg BID
Aclidinium bromide/formoterol fumarate 400/12μg administered by inhalation via the Genuair® multidose dry powder inhaler, twice daily (morning and evening) for 5 days




Primary Outcome Measures :
  1. Cmax of Aclidinium Bromide, Its Metabolites and Formoterol Fumarate (Single Dose). [ Time Frame: Pre-dose and 5, 15, and 30 minutes, and 1, 1.5, 2, 3, 4, 6, 8, and 12 hours post the morning dose on Day 1 ]
    Observed maximum concentration, taken directly from the individual concentration-time curve (first dose).

  2. Tmax of Aclidinium Bromide, Its Metabolites and Formoterol Fumarate (Single Dose). [ Time Frame: Pre-dose and 5, 15, and 30 minutes, and 1, 1.5, 2, 3, 4, 6, 8, and 12 hours post the morning dose on Day 1 ]
    Time to maximum concentration (h), taken directly from the individual concentration-time curve (first dose).

  3. Cmin of Aclidinium Bromide, Its Metabolites and Formoterol Fumarate (Single Dose). [ Time Frame: Pre-dose and 5, 15, and 30 minutes, and 1, 1.5, 2, 3, 4, 6, 8, and 12 hours post the morning dose on Day 1 ]
    Minimum plasma drug concentration at the end of the dosing interval (first dose), where possible.

  4. AUC(Last) of Aclidinium Bromide, Its Metabolites and Formoterol Fumarate (Single Dose). [ Time Frame: Pre-dose and 5, 15, and 30 minutes, and 1, 1.5, 2, 3, 4, 6, 8, and 12 hours post the morning dose on Day 1 ]
    Area under the plasma concentration-curve from time zero to the time of last quantifiable analyte concentration.

  5. AUC(Tau) of Aclidinium Bromide, Its Metabolites and Formoterol Fumarate (Single Dose). [ Time Frame: Pre-dose and 5, 15, and 30 minutes, and 1, 1.5, 2, 3, 4, 6, 8, and 12 hours post the morning dose on Day 1 ]
    Area under the plasma concentration curve during the first dosing interval, tau (first dose).

  6. Css,Max of Aclidinium Bromide, Its Metabolites and Formoterol Fumarate (Multiple Doses). [ Time Frame: Pre-dose and 5, 15, and 30 minutes, and 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours post the morning dose on Day 5 ]
    Observed maximum concentration, taken directly from the individual concentration-time curve at steady state.

  7. Css,Min of Aclidinium Bromide, Its Metabolites and Formoterol Fumarate (Multiple Doses). [ Time Frame: Pre-dose and 5, 15, and 30 minutes, and 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours post the morning dose on Day 5 ]
    Observed minimum concentration, taken directly from the individual concentration-time curve within a dosing interval on Day 5.

  8. Tss,Max of Aclidinium Bromide, Its Metabolites and Formoterol Fumarate (Multiple Doses). [ Time Frame: Pre-dose and 5, 15, and 30 minutes, and 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours post the morning dose on Day 5 ]
    Time to maximum concentration (h), taken directly from the individual concentration-time curve at steady state.

  9. λz of Aclidinium Bromide, Its Metabolites and Formoterol Fumarate (Multiple Doses). [ Time Frame: Pre-dose and 5, 15, and 30 minutes, and 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours post the morning dose on Day 5 ]
    Terminal rate constant, estimated by log-linear least square regression of the terminal part of the concentration-time curve.

  10. t½λz of Aclidinium Bromide, Its Metabolites and Formoterol Fumarate (Multiple Doses). [ Time Frame: Pre-dose and 5, 15, and 30 minutes, and 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours post the morning dose on Day 5 ]
    Terminal half-life (h), estimated as (ln2)/λz.

  11. AUC(ss,Tau) of Aclidinium Bromide, Its Metabolites and Formoterol Fumarate (Multiple Doses). [ Time Frame: Pre-dose and 5, 15, and 30 minutes, and 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours post the morning dose on Day 5 ]
    Area under the plasma concentration curve during the dosing interval, tau at steady state.

  12. CL/F of Aclidinium Bromide and Formoterol Fumarate (Multiple Doses). [ Time Frame: Pre-dose and 5, 15, and 30 minutes, and 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours post the morning dose on Day 5 ]
    Apparent plasma clearance for parent drug estimated as dose divided by AUCss

  13. Vz/F of Aclidinium Bromide and Formoterol Fumarate (Multiple Doses). [ Time Frame: Pre-dose and 5, 15, and 30 minutes, and 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours post the morning dose on Day 5 ]
    Apparent volume of distribution for parent drug at terminal phase, estimated by dividing the apparent clearance (CL/F) by λz.

  14. Cav of Aclidinium Bromide, Its Metabolites and Formoterol Fumarate (Multiple Doses). [ Time Frame: Pre-dose and 5, 15, and 30 minutes, and 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours post the morning dose on Day 5 ]
    Average plasma concentration during a dosing interval, estimated as AUC(ss,tau)/12

  15. %Fluctuation of Aclidinium Bromide, Its Metabolites and Formoterol Fumarate (Multiple Doses). [ Time Frame: Pre-dose and 5, 15, and 30 minutes, and 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours post the morning dose on Day 5 ]
    Fluctuation index during a dosing interval estimated as 100*(Cmax-Cmin)/Cav (%).

  16. Rac(Cmax) of Aclidinium Bromide, Its Metabolites and Formoterol Fumarate (Multiple Doses). [ Time Frame: Pre-dose and 5, 15, and 30 minutes, and 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours post the morning dose on Day 5 ]
    Accumulation ratio for Cmax estimated as Css,max on Day 5/Cmax on Day 1

  17. Rac[AUC(Tau)] of Aclidinium Bromide, Its Metabolites and Formoterol Fumarate (Multiple Doses). [ Time Frame: Pre-dose and 5, 15, and 30 minutes, and 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours post the morning dose on Day 5 ]
    Accumulation ratio for AUC(tau) estimated as AUC(ss,tau) on Day 5/AUC(tau) on Day 1

  18. Rac(Cmin) of Aclidinium Bromide, Its Metabolites and Formoterol Fumarate (Multiple Doses). [ Time Frame: Pre-dose and 5, 15, and 30 minutes, and 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours post the morning dose on Day 5 ]

    Accumulation ratio for Cmin estimated as Css,min on Day 5/Cmin on Day 1.

    Additional parameters may be determined where appropriate.



Secondary Outcome Measures :
  1. Adverse Events (AEs)/Serious AEs (SAEs) [ Time Frame: Screening (Day -21) to Follow-up visit (Days 8-12) ]
    Assessment of the safety in terms of the incidences of AEs/SAEs after administration of Aclidinium Bromide/Formoterol Fumarate 400/12 μg BID for 5 days.

  2. Treatment-emergent AEs Related to Blood Pressure [ Time Frame: Screening (Day -21) to Follow-up visit (Days 8-12) ]
    Assessment of the safety in terms of notable changes from baseline in blood pressure after administration of Aclidinium Bromide/Formoterol Fumarate 400/12 μg BID for 5 days.

  3. Treatment-emergent AEs Related to Clinical Laboratory Parameters (Haematology) [ Time Frame: Screening (Day -21) to Follow-up visit (Days 8-12) ]
    Assessment of the safety in terms of haematology parameters after administration of Aclidinium Bromide/Formoterol Fumarate 400/12 μg BID for 5 days.

  4. Treatment-emergent AEs Related to Clinical Laboratory Parameters (Urinalysis) [ Time Frame: Screening (Day -21) to Follow-up visit (Days 8-12) ]
    Assessment of the safety in terms of urinalysis parameters after administration of Aclidinium Bromide/Formoterol Fumarate 400/12 μg BID for 5 days.

  5. Treatment-emergent AEs Related to Clinical Laboratory Parameters (Serum Biochemistry) [ Time Frame: Screening (Day -21) to Follow-up visit (Days 8-12) ]
    Assessment of the safety in terms of serum biochemistry parameters (Alanine aminotransferase [ALT], Aspartate aminotransferase [AST], alkaline phosphatase [ALP], Gamma-glutamyl transferase [GGT], bilirubin, creatine kinase, lactate dehydrogenase, urea nitrogen, creatinine, urate, cholesterol, glucose, sodium, potassium, calcium, chloride, phosphate, protein, and albumin) after administration of Aclidinium Bromide/Formoterol Fumarate 400/12 μg BID for 5 days.

  6. Treatment-emergent AEs Related to 12-lead ECG Parameters [ Time Frame: Screening (Day -21) to Follow-up visit (Days 8-12) ]
    Assessment of the safety in terms of the 12-lead ECG parameters after administration of Aclidinium Bromide/Formoterol Fumarate 400/12 μg BID for 5 days.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 130 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Ability to communicate with medical team and staff, willing to participate in the trial, willing to give written informed consent, and comply with the trial procedures and restrictions.
  • Chinese men or non-pregnant, non-lactating women, aged ≥40 years old at Visit 1 (Screening).
  • Patients with a diagnosis of COPD (GOLD guidelines) for a period of at least 6 months prior to Visit 1 (screening).
  • Current or former smokers with a smoking history of ≥10 pack-years.
  • Patients with moderate to severe stable COPD (Stage II or Stage III, according to GOLD Guidelines) at Visit 1: post-bronchodilator FEV1 ≥30% and <80% and post-bronchodilator FEV1/FVC <70%.
  • Must be able to perform repeatable pulmonary function testing for FEV1 according to ATS/ERS 2005 criteria at Visit 1 (Screening).

Exclusion Criteria:

  • Involvement in the planning and/or conduct of the study (applies to AstraZeneca staff and/or site staff) or patients employed by or relatives of the employees of the site or sponsor.
  • Previous enrolment or randomisation in the present study.
  • History or current diagnosis of asthma.
  • Any respiratory tract infection (including the upper respiratory tract) or COPD exacerbation (including the mild COPD exacerbation) within 6 weeks prior to screening or during the run-in period.
  • Patients hospitalized for COPD exacerbation (an emergency room visit for longer than 24 hours will be considered a hospitalization) within 3 months prior to screening and during the run-in period.
  • Use of long-term oxygen therapy ≥15 hours per day.
  • Patient with a history of hypersensitivity reaction to inhaled anticholinergics, sympathomimetic amines, inhaled medication, or any component thereof.
  • Patients with known narrow-angle glaucoma, symptomatic bladder neck obstruction, acute urinary retention, or patients with symptomatic nonstable prostatic hypertrophy.
  • Patients with Type I or uncontrolled Type II diabetes, uncontrolled hypothyroidism or hyperthyroidism, hypokalaemia, hyperadrenergic state, or uncontrolled or untreated hypertension.
  • Clinically significant cardiovascular conditions.
  • Patient with resting systolic blood pressure ≥160 mmHg, a resting diastolic blood pressure ≥100 mmHg, or a resting heart rate ≤50 bpm or ≥100 bpm at Visit 1 (Screening) or/and at Visit 2 (Day -1 to Day 7).
  • Have a body mass index (BMI) ≥40 kg/m2
  • Electrocardiogram (ECG) at Screening or Day -1 showing corrected QT interval (QTc) using Fridericia's correction (QTcF) >470 msec.
  • Patients with clinically relevant abnormalities in the results of the laboratory tests, ECG parameters (other than QTcF), or in the physical examination at Visit 1, except those related to COPD.
  • Positive results for drugs of abuse in the urine at Visit 1 (Screening).
  • Positive test for hepatitis B surface antigen (HBsAg), hepatitis C antibody and/or human immunodeficiency virus (HIV) I antibodies at Visit 1 (Screening).
  • History of malignancy of any organ system (including lung cancer), treated or untreated, within the past 5 years other than basal or squamous cell skin cancer.
  • Any other serious or uncontrolled physical or mental condition/disease.
  • Patient with a history (within 2 years prior to Visit 1 [Screening]) of drug and/or alcohol abuse that may prevent trial compliance based on investigator judgment.
  • Taken any medication within 14 days before the first dose of IP, or hormonal drug products and traditional Chinese medicines within 30 days before the first dose of IP, with the exception of allowed medications listed in the study protocol.
  • Participation in any other clinical investigation using an experimental drug requiring repeated blood or plasma drawn within 60 days of Day 1 at Visit 2.
  • Have participated in a blood/plasma donation or blood loss greater than 400 mL within 90 days or greater than 200 mL within 30 days prior to Visit 1 (Screening).
  • Have any clinical condition that might affect the absorption, distribution, biotransformation, or excretion of Aclidinium Bromide/Formoterol Fumarate.
  • Have consumed caffeine or any grapefruit-containing products within 48 hours or alcohol within 72 hours before Day -1 at Visit 2.
  • Inability to be venipunctured or tolerate venous access as determined by the investigator or designee.
  • Inability to use a multidose DPI.
  • Subjects unable to give their consent, or subjects of consenting age but under guardianship, or vulnerable subjects.
  • In the opinion of the PI, subjects who are unlikely to comply with the protocol requirements, instructions, and trial-related restrictions.
  • Previously taken Aclidinium or previously participated in an investigational study of Aclidinium within 6 months of Day 1

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03276078


Locations
Layout table for location information
China
Research Site
Changchun, China, 130021
Sponsors and Collaborators
AstraZeneca
Investigators
Layout table for investigator information
Principal Investigator: Zhenxiang Yu Pneumology Department, The First Hospital of Jilin University
  Study Documents (Full-Text)

Documents provided by AstraZeneca:
Statistical Analysis Plan  [PDF] July 3, 2018
Study Protocol  [PDF] March 24, 2017

Additional Information:
Layout table for additonal information
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT03276078    
Other Study ID Numbers: D6572C00001
M-AS464-01 ( Other Identifier: Clinical Trial Protocol Code )
First Posted: September 8, 2017    Key Record Dates
Results First Posted: July 22, 2019
Last Update Posted: July 22, 2019
Last Verified: May 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by AstraZeneca:
COPD
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Bromides
Formoterol Fumarate
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Anticonvulsants